Skip to main content
SoftOx Solutions AS logo

SoftOx Solutions AS — Investor Relations & Filings

Ticker · SOFTX ISIN · NO0010811961 LEI · 549300AETMWJS91G4A50 OL Manufacturing
Open in API
Filings indexed 574 across all filing types
Latest filing 2020-10-22 Regulatory Filings
Country NO Norway
Listing OL SOFTX

About SoftOx Solutions AS

https://soft-ox.com/

SoftOx Solutions AS is a clinical-stage pharmaceutical company that has developed a patented, non-toxic antimicrobial technology. The technology is based on a stabilized formulation of hypochlorous acid (HOCl), an endogenous molecule used by the human immune system to combat pathogens. It is designed to be highly effective against a broad spectrum of bacteria, viruses, and fungi, and to eradicate and prevent biofilm infections. A key feature of the technology is that its mode of action does not induce antimicrobial resistance (AMR). The company's development pipeline focuses on significant health challenges, with a lead candidate, SoftOx Inhalation Solution (SIS), for treating airway infections, as well as other applications in wound care and disinfection.

Recent filings

Filing Released Lang Actions
- SoftOx er nærmere et mulig gjennombrudd i kampen om å bekjempe COVID-19
Regulatory Filings Classification · 99% confidence The document is a short press release announcing positive regulatory feedback from the Danish Medicines Agency regarding the development path for SoftOx Solutions' inhalation treatment for respiratory infections, including COVID-19. It discusses future clinical trial timelines and market potential. Since it is a brief announcement about a development update rather than a comprehensive financial report (like 10-K or IR), a management change (MANG), or a formal dividend notice (DIV), it fits best under the general category for regulatory or corporate announcements that aren't covered by more specific codes. Given the content focuses on scientific/regulatory progress and is presented as a news update, it is most appropriately classified as a Regulatory Filing (RNS) as a general announcement, or potentially an Investor Presentation (IP) if it were a slide deck, but here it reads like a press release. Considering the options, RNS (Regulatory Filings / miscellaneous announcements) is the most suitable fallback for this type of corporate news release that isn't a formal financial filing or a specific event announcement like AGM or ER.
2020-10-22 Norwegian
- SoftOx closer to a possible breakthrough in the fight against COVID-19
Regulatory Filings Classification · 95% confidence The document is a short press release or news item announcing a positive development regarding the company's COVID-19 treatment candidate (SoftOx inhalation solution) following a recommendation from the Danish Medicines Agency. It discusses potential future human testing timelines and market size. It is not a formal regulatory filing like a 10-K, IR, or ER. Since it is an announcement about scientific/product progress and does not fit into specific categories like M&A (TAR), Capital Change (CAP), or Dividend (DIV), it best fits the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory or significant operational announcements that aren't covered elsewhere. Given the content is an update on a product/scientific path, RNS is the most appropriate general classification.
2020-10-22 English
KLINISK STUDIE FOR SOFTOX’ SÅRSKYLL GODKJENT OG KLAR FOR OPPSTART.
Regulatory Filings Classification · 92% confidence The document is a short announcement dated October 19, 2020, written in Norwegian. It states that a clinical study ('SWIS-02') for SoftOx's wound irrigation solution has been approved by Danish regulatory authorities (Lægemiddelstyrelsen and Scientific Ethics Committees). The text focuses on regulatory approval for a clinical trial and the subsequent start of the study, positioning the product for the European market. This type of announcement, detailing progress in product development and regulatory milestones, does not fit neatly into standard financial reports (10-K, IR, ER) or specific corporate actions (DIV, SHA, M&A). Given its nature as a specific, non-standard regulatory or operational update that doesn't match the defined categories like 'LTR' (Legal Proceedings) or 'CAP' (Financing), the most appropriate fallback category is 'RNS' (Regulatory Filings) for general regulatory announcements that don't fit elsewhere.
2020-10-19 Norwegian
CLINICAL STUDY FOR SOFTOX WOUND RINSE READY FOR START-UP
Regulatory Filings Classification · 90% confidence The document announces that a clinical study ('SWIS-02') for the product 'SoftOx Wound Irrigation Solution (SWIS)' has received full regulatory approval from the Danish Medicines Agency (DMA) and the Health Research Ethics Committee, and that the study will commence in November 2020. This content relates to the development and regulatory status of a medical device/product, but it is not a formal financial report (like 10-K, IR, ER) nor is it a standard investor presentation (IP). It is a specific operational update concerning regulatory milestones and clinical trials. Given the options, this type of announcement, which details progress in product development and regulatory hurdles, most closely aligns with a general regulatory announcement or a specific operational update that doesn't fit the other categories. Since it is an announcement about a regulatory step (approval for a clinical investigation), and it is not a standard financial filing, 'Regulatory Filings' (RNS) serves as the best general category for non-standard, specific operational/regulatory news releases that don't fit the defined financial or governance codes. It is not a Call Transcript (CT), Earnings Release (ER), or a formal Audit Report (AR).
2020-10-19 English
Første halvår 2020, presentasjon for dagens webinar i samarbeid med Arctic securities og Sparebanken 1, kl. 1230
Investor Presentation Classification · 95% confidence The document is a presentation deck for SoftOx Solutions AS, detailing their product portfolio, market strategy, and financial highlights for Q2 2020. It contains strategic business information, market analysis, and financial tables, which is characteristic of an investor presentation used to communicate company strategy and performance to stakeholders. Q2 2020
2020-09-30 Norwegian
1st half year 2020, presentation for today's webinar in collaboration with Arctic securities and Sparebanken 1, at 1230PM CET
Investor Presentation Classification · 95% confidence The document is a presentation deck for SoftOx Solutions AS, detailing their product portfolio, market strategy, and financial highlights for Q2 2020. It contains strategic business information, market analysis, and financial tables, which is characteristic of an investor presentation used to communicate company strategy and performance to stakeholders. Q2 2020
2020-09-30 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.